Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec 28;9(36):1340-1345.
doi: 10.4254/wjh.v9.i36.1340.

Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1

Yoshinori Ozono  1 , Kenji Nagata  2 , Satoru Hasuike  1 , Hisayoshi Iwakiri  1 , Kenichi Nakamura  1 , Mai Tsuchimochi  3 , Yuri Yamada  1 , Yuka Takaishi  1 , Mitsue Sueta  1 , Tadashi Miike  1 , Yoshihiro Tahara  1 , Shojiro Yamamoto  1 , Kotaro Shide  1 , Tomonori Hidaka  1 , Yoko Kubuki  1 , Kazunori Kusumoto  4 , Toshimasa Ochiai  4 , Junya Kato  5 , Naoto Komada  5 , Shuichi Hirono  6 , Kazuo Kuroki  7 , Masafumi Shigehira  8 , Kazuya Shimoda  1
Affiliations

Efficacy and safety of sofosbuvir and ledipasvir in Japanese patients aged 75 years or over with hepatitis C genotype 1

Yoshinori Ozono et al. World J Hepatol. .

Abstract

Aim: To evaluate the efficacy and safety of a regimen containing sofosbuvir (SOF) and ledipasvir (LDV) in Japanese patients aged ≥ 75 years with hepatitis C genotype 1.

Methods: This multicenter, retrospective study consisted of 246 Japanese patients with HCV genotype 1 at nine centers in Miyazaki prefecture in Japan. Demographic, clinical, virological, and adverse effects (AE)-related data obtained during and after SOF/LDV therapy were collected from medical records. These patients were divided into two groups, younger (aged < 75 years) and elderly (aged ≥ 75 years). Virological data and AEs were analyzed by age group.

Results: The sustained virological response (SVR) rates at 12 wk after treatment were 99.2%, 99.4%, and 98.7% in the overall population and in patients aged < 75 and ≥ 75 years, respectively. Common AEs during therapy were headache, pruritus, constipation, and insomnia. These occurred in fewer than 10% of patients, and their incidence was not significantly different between the younger and elderly groups. Two patients discontinued treatment, one due to a skin eruption and the other due to cerebral bleeding.

Conclusion: Compared with younger patients, elderly patients had a similar virological response and tolerance to SOF/LDV therapy.

Keywords: Chronic hepatitis C; Direct acting antivirals; Ledipasvir; Sofosbuvir; Sustained virological response.

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest statement: There are no conflict-of-interests involved in the article.

References

    1. Hoofnagle JH. Course and outcome of hepatitis C. Hepatology. 2002;36:S21–S29. - PubMed
    1. Seeff LB. Natural history of chronic hepatitis C. Hepatology. 2002;36:S35–S46. - PubMed
    1. Bennett H, Waser N, Johnston K, Kao JH, Lim YS, Duan ZP, Lee YJ, Wei L, Chen CJ, Sievert W, et al. A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. Hepatol Int. 2015;9:378–390. - PubMed
    1. Tanaka J, Koyama T, Mizui M, Uchida S, Katayama K, Matsuo J, Akita T, Nakashima A, Miyakawa Y, Yoshizawa H. Total numbers of undiagnosed carriers of hepatitis C and B viruses in Japan estimated by age- and area-specific prevalence on the national scale. Intervirology. 2011;54:185–195. - PubMed
    1. Karino Y. Innovation in Hepatitis C Treatment. J Jpn Assoc Rural Med. 2016;65:129–135.

LinkOut - more resources